Pfizer raises 2026 outlook as third-quarter sales grow
Pfizer raised its 2026 performance outlook, citing third-quarter growth from Eliquis and cancer medicines. Eliquis sales rose 25%. Cecile Guegan was named chief financial officer.
Related stories
Italian Stocks Close Flat
Milan’s FTSE MIB closed largely unchanged at 49,942 on Tuesday as investors assessed the latest batch of third-quarter earnings. Lottomatica gained 0.9% after reporting a 5% year-o
H impact | EARNINGS | Nov 03, 2026, 05:03 PM UTC
Sacyr Reports 9-Month Net Profit of €116.3 Million
M impact | EARNINGS | Nov 03, 2026, 04:54 PM UTC
Meliá Hotels Reports Q3 EBITDA of €198.3 Million
M impact | EARNINGS | Nov 03, 2026, 04:54 PM UTC
Sacyr Reports Nine-Month Revenue of €3.78 LN
M impact | EARNINGS | Nov 03, 2026, 04:53 PM UTC
Sacyr Reports Nine-Month EBITDA of €1.11 Billion
M impact | EARNINGS | Nov 03, 2026, 04:53 PM UTC
Groupe BPCE Q3 Net Income Rises 25% to €1.4B
Groupe BPCE reported Q3-26 net banking income of €7.0B, up 9% year over year. Nine-month net income was €3.8B, up 28%.
M impact | EARNINGS | Nov 03, 2026, 04:52 PM UTC